Страна: Канада
мова: англійська
Джерело: Health Canada
IBUPROFEN; METHOCARBAMOL
TEVA CANADA LIMITED
M03BA53
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
200MG; 500MG
TABLET
IBUPROFEN 200MG; METHOCARBAMOL 500MG
ORAL
18/40
OTC
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0248961001; AHFS:
CANCELLED POST MARKET
2021-08-12
1 | P a g e PRODUCT MONOGRAPH ANALGESIC & MUSCLE RELAXANT CAPLETS 500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS THERAPEUTIC CLASSIFICATION MUSCLE RELAXANT / ANALGESIC TEVA CANADA LIMITED Date of Preparation: 30 Novopharm Court January 8, 2013 Toronto, Canada M1B 2K9 Control# 161025 2 | P a g e TABLE OF CONTENTS Clinical Pharmacology .............................................................................................................................. 3 Indications: ................................................................................................................................................ 7 Contraindications ...................................................................................................................................... 8 Warnings: .................................................................................................................................................. 8 Precautions .............................................................................................................................................. 12 Drug Interactions .................................................................................................................................... 13 Adverse Reactions .................................................................................................................................. 15 Symptoms and Treatment of Overdose ................................................................................................... 17 Dosage and Administration..................................................................................................................... 18 Pharmaceutical Information .................................................................................................................... 19 Composition: ........................................................................................................................................... 21 Availability of Dosage Forms .......................... Прочитайте повний документ